SEC Tracker
Get the app

Cogent Biosciences COGT

Cogent Biosciences Q3 FY23: net loss $55.4M; diluted EPS −$0.64

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Cogent Biosciences reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$55.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.64No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$86.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$38.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Cogent Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. uniQure QURE public float $765M, Jun 30, 2025
  2. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  3. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  4. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  5. Nurix Therapeutics NRIX public float $808M, May 30, 2025